Literature DB >> 32998876

Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.

Jasmohan S Bajaj1, Masoumeh Sikaroodi2, Amirhossein Shamsaddini2, Zachariah Henseler3, Tasha Santiago-Rodriguez3, Chathur Acharya4, Andrew Fagan4, Phillip B Hylemon4, Michael Fuchs4, Edith Gavis4, Tonya Ward3, Dan Knights3,5,6, Patrick M Gillevet2.   

Abstract

OBJECTIVE: Altered bacterial composition is associated with disease progression in cirrhosis but the role of virome, especially phages, is unclear.
DESIGN: Cross-sectional and pre/post rifaximin cohorts were enrolled. Cross-sectional: controls and cirrhotic outpatients (compensated, on lactulose (Cirr-L), on rifaximin (Cirr-LR)) were included and followed for 90-day hospitalisations. Pre/post: compensated cirrhotics underwent stool collection pre/post 8 weeks of rifaximin. Stool metagenomics for bacteria and phages and their correlation networks were analysed in controls versus cirrhosis, within cirrhotics, hospitalised/not and pre/post rifaximin.
RESULTS: Cross-sectional: 40 controls and 163 cirrhotics (63 compensated, 43 Cirr-L, 57 Cirr-LR) were enrolled. Cirr-L/LR groups were similar on model for end-stage liver disease (MELD) score but Cirr-L developed greater hospitalisations versus Cirr-LR (56% vs 30%, p=0.008). Bacterial alpha/beta diversity worsened from controls through Cirr-LR. While phage alpha diversity was similar, beta diversity was different between groups. Autochthonous bacteria linked negatively, pathobionts linked positively with MELD but only modest phage-MELD correlations were seen. Phage-bacterial correlation network complexity was highest in controls, lowest in Cirr-L and increased in Cirr-LR. Microviridae and Faecalibacterium phages were linked with autochthonous bacteria in Cirr-LR, but not Cirr-L hospitalised patients had greater pathobionts, lower commensal bacteria and phages focused on Streptococcus, Lactococcus and Myoviridae. Pre/post: No changes in alpha/beta diversity of phages or bacteria were seen postrifaximin. Phage-bacterial linkages centred around urease-producing Streptococcus species collapsed postrifaximin.
CONCLUSION: Unlike bacteria, faecal phages are sparsely linked with cirrhosis characteristics and 90-day outcomes. Phage and bacterial linkages centred on urease-producing, ammonia-generating Streptococcus species were affected by disease progression and rifaximin therapy and were altered in patients who experienced 90-day hospitalisations. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cirrhosis; hepatic encephalopathy; intestinal microbiology; liver

Mesh:

Substances:

Year:  2020        PMID: 32998876     DOI: 10.1136/gutjnl-2020-322470

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

Review 1.  Intestinal virome and therapeutic potential of bacteriophages in liver disease.

Authors:  Cynthia L Hsu; Yi Duan; Derrick E Fouts; Bernd Schnabl
Journal:  J Hepatol       Date:  2021-08-24       Impact factor: 25.083

Review 2.  Bacteriophages and their potential for treatment of gastrointestinal diseases.

Authors:  Yi Duan; Ry Young; Bernd Schnabl
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-11-15       Impact factor: 46.802

Review 3.  Promises of microbiome-based therapies.

Authors:  Jasmohan S Bajaj; Siew C Ng; Bernd Schnabl
Journal:  J Hepatol       Date:  2022-06       Impact factor: 30.083

Review 4.  The microbiota in cirrhosis and its role in hepatic decompensation.

Authors:  Jonel Trebicka; Jane Macnaughtan; Bernd Schnabl; Debbie L Shawcross; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

5.  Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis.

Authors:  Amirhossein Shamsaddini; Patrick M Gillevet; Chathur Acharya; Andrew Fagan; Edith Gavis; Masoumeh Sikaroodi; Sara McGeorge; Alexander Khoruts; Somaya Albhaisi; Michael Fuchs; Richard K Sterling; Jasmohan S Bajaj
Journal:  Gastroenterology       Date:  2021-04-20       Impact factor: 33.883

Review 6.  Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease.

Authors:  Chathur Acharya; Jasmohan S Bajaj
Journal:  Gastroenterology       Date:  2020-11-28       Impact factor: 33.883

Review 7.  COVID-19-associated liver injury: from bedside to bench.

Authors:  Dongxiao Li; Xiangming Ding; Meng Xie; Dean Tian; Limin Xia
Journal:  J Gastroenterol       Date:  2021-02-01       Impact factor: 7.527

Review 8.  Lights and Shadows in Hepatic Encephalopathy Diagnosis.

Authors:  Piero Amodio; Sara Montagnese
Journal:  J Clin Med       Date:  2021-01-18       Impact factor: 4.241

Review 9.  Human Gut Microbiome and Liver Diseases: From Correlation to Causation.

Authors:  Rui Li; Zhengsheng Mao; Xujun Ye; Tao Zuo
Journal:  Microorganisms       Date:  2021-05-08

Review 10.  The Gut-Liver Axis in Cholestatic Liver Diseases.

Authors:  Andreas Blesl; Vanessa Stadlbauer
Journal:  Nutrients       Date:  2021-03-21       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.